 The independent Data Safety Monitoring Board DSMB has recommended concluding enrollment in PolyPid Ltds NASDAQ: PYPD SHIELD I Phase 3 study of D-PLEX100 to prevent surgical site infections SSIs abdominal tissue surgery. DSMB recommended stopping enrollment upon 950. 